From Yahoo Finance · · 1m 30s
Tempus AI Shares Jump 30% After Morgan Stanley Revenue Boost
Morgan Stanley's revenue outlook boost lifts Tempus AI shares 30% this week.
In brief
Morgan Stanley's revenue outlook boost lifts Tempus AI shares 30% this week. Morgan Stanley's revised revenue projections for Tempus AI's diagnostics services boosted shares 30% this week, with $330M to $400M in annual revenue potential. Originally reported by Yahoo Finance.
Tempus AI Shares Surge
Tempus AI shares rose 30% this week after Morgan Stanley highlighted reimbursement pricing that could add $330 million to $400 million in annual revenue across xT and xF diagnostics.
CEO Lefkofsky Projects Growth
CEO Eric Lefkofsky stated Tempus will exceed its 25% multiyear growth target, with $200 million in Q2 data licensing bookings from AstraZeneca, GSK, and Merck.
Revenue Projections
Morgan Stanley estimates xT pricing adds $80 million to $100 million next year, while xF approval and pricing could add $250 million to $300 million annually.
Market Reaction
Shares trade at 9x sales, below their 52-week high of $104.32 despite a 54.24% one-month gain, with the $68.18 analyst target lagging the market price.
Q2 Data Licensing
Q2 revenue reached $382.49 million, up 21.6% year over year, with oncology testing volumes accelerating 31%.
Analyst Sentiment Shift
Forward EPS estimates for fiscal 2027 have swung from -$0.1067 ninety days ago to $0.0040 today, with eight upward revisions in the past 30 days.
What's Next
Tempus AI's reimbursement clarity and pending Personalis deal could drive positive free cash flow by year end, despite ongoing GAAP losses and high stock-based compensation.
The big picture
Morgan Stanley's revised revenue projections for Tempus AI's diagnostics services boosted shares 30% this week, with $330M to $400M in annual revenue potential.
